Retatrutide
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports
Retatrutide, a triple action treatment for type 2 diabetes, could significantly reduce blood glucose concentrations and body weight in patients with the condition, a phase 3 trial has reported. The results, published in the Lancet,1 show that patients who received injections of retatrutide for 40 weeks lost more than four times as much weight as those in the placebo group. After 40 weeks the average reduction in HbA1c with the new treatment was more than twice that in the placebo group,...
Gym influencer who sells weight loss jabs on social media unmasked as convicted drug dealer
Gym influencer who sells weight loss jabs on social media unmasked as convicted drug dealer EXCLUSIVE: Mark Allen, 46, was sentenced to two-and-a-half years behind bars for possession of crack cocaine and heroin with intent to supply - now he is selling weight loss injections online A fitness influencer who flogs weight loss jabs on social media is a convicted drug dealer. Mark Allen, 46, plugs peptides on his Weight Loss and Gym Gains page including Retatrutide, which is not approved for...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
Eli Lilly 's expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to record highs. "It's a parabolic spike. I don't buy parabolas," Jim Cramer said on " Squawk on the Street " on Monday.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer injections. Pfizer and Amgen are developing monthly GLP-1 shots — a departure from injections like Wegovy and Zepbound, which are taken weekly.
Health authorities launch crackdown on illegal peptides, amid surge in use
TGA cracks down on unregulated peptides, says increased imports are posing a risk to consumer safety Wed 10 Jun 2026 at 5:00pm In short: The Therapeutic Goods Administration has named unapproved peptides as a new priority focus area.